The newest generation of injectable medications—GLP-1 drugs like Ozempic, Wegovy, and Zepbound—have already transformed treatment for type 2 diabetes and obesity. But their potential impact doesn’t stop there. Over 400 clinical trials are underway worldwide, investigating whether these drugs can treat or prevent conditions ranging from heart disease and stroke to polycystic ovary syndrome (PCOS) and even cancer.
Why are GLP-1s so versatile? The answer lies in their broad effects on the body. Experts believe many chronic diseases stem from disruptions in insulin resistance and chronic inflammation—and these drugs address both. As Dr. Jamy Ard of Wake Forest University explains, “There is no organ system that is not affected by this internal metabolic environment.” GLP-1 drugs don’t just help people eat less; they also influence blood sugar, inflammation, and potentially other key biological processes.
GLP-1 receptors aren’t limited to the pancreas. They’re found throughout the body, including the brain, cardiovascular system, gut, kidneys, and immune system. This widespread distribution explains why researchers are exploring their use in so many different conditions.
FDA-Approved Uses Expanding
The FDA has already approved GLP-1s for more than just diabetes and weight loss.
- Heart Disease: In March 2024, Wegovy was approved to treat heart disease in overweight and obese individuals, after trials showed a 20% reduction in heart attacks, strokes, and cardiovascular death compared to placebo. This suggests the drugs offer benefits beyond weight loss alone.
- Sleep Apnea: Zepbound received approval in December 2024 for moderate-to-severe obstructive sleep apnea in obese adults, significantly reducing symptoms.
- Kidney Disease: Semaglutide (Ozempic) has been approved to slow the progression of chronic kidney disease in people with diabetes, reducing the risk of kidney failure and cardiovascular death by 24%.
- Liver Disease: Wegovy was approved in August 2025 for metabolic-associated steatohepatitis (MASH), a severe form of fatty liver disease, improving liver inflammation and even reducing scarring.
Promising Research Areas
Beyond approved uses, trials are exploring GLP-1s for conditions like:
- Osteoarthritis: Studies suggest they may slow disease progression and reduce the need for knee surgery.
- Psoriasis: A large study found GLP-1 users with psoriasis had a 78% lower risk of death and a 44% lower risk of major cardiovascular events.
- Polycystic Ovary Syndrome (PCOS): GLP-1s may improve insulin resistance, testosterone levels, and even ovulation rates in women with PCOS.
- Rheumatoid Arthritis: Patients with RA taking GLP-1s showed improvements in disease activity and pain, alongside better metabolic markers.
- Cancer Prevention: Population studies suggest potential reductions in obesity-related cancers, particularly colorectal cancer, though more research is needed.
The Bigger Picture: These findings suggest GLP-1 drugs could reshape how we approach chronic disease. By targeting underlying metabolic dysfunction, they may offer a way to prevent or delay the progression of conditions previously treated only with symptom management.
The evidence is mounting that these medications are not just about weight loss—they are about systemic health improvement. This shift could expand insurance coverage and access to these drugs, transforming the landscape of chronic disease management.
